These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 10172918)

  • 1. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
    Goa KL; Barradell LB; McTavish D
    Pharmacoeconomics; 1997 Jan; 11(1):89-110. PubMed ID: 10172918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-benefit analysis of lipid lowering therapy.
    Davie AP; McMurray JJ
    Eur Heart J; 1996 Jul; 17(7):974-5. PubMed ID: 8809507
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-benefit analysis of lipid lowering therapy.
    Jönsson B; Johannesson M
    Eur Heart J; 1997 Jan; 18(1):165-6. PubMed ID: 9049529
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S).
    Jönsson B; Johannesson M; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    Eur Heart J; 1996 Jul; 17(7):1001-7. PubMed ID: 8809516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
    Rivière M; Wang S; Leclerc C; Fitzsimon C; Tretiak R
    CMAJ; 1997 Apr; 156(7):991-7. PubMed ID: 9099167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of coronary heart disease prevention strategies in adults.
    Brown AD; Garber AM
    Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.
    Chrisp P; Lewis NJ; Milne RJ
    Pharmacoeconomics; 1992 Feb; 1(2):124-45. PubMed ID: 10146941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
    Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
    Perreault S; Hamilton VH; Lavoie F; Grover S
    Arch Intern Med; 1998 Feb; 158(4):375-81. PubMed ID: 9487235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.
    Hay JW; Yu WM; Ashraf T
    Pharmacoeconomics; 1999 Jan; 15(1):47-74. PubMed ID: 10345158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
    Pedersen TR; Tobert JA
    Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA; Coupal L; Paquet S; Zowall H
    Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of 4S evidence on baseline lipid levels.
    Jacobson TA
    Lancet; 1995 Jul; 346(8968):181-2. PubMed ID: 7603245
    [No Abstract]   [Full Text] [Related]  

  • 15. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.
    Jönsson B; Cook JR; Pedersen TR
    Diabetologia; 1999 Nov; 42(11):1293-301. PubMed ID: 10550412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands.
    Martens LL; Rutten FF; Erkelens DW; Ascoop CA
    Am J Cardiol; 1990 Mar; 65(12):27F-32F. PubMed ID: 2107736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 4S study and its pharmacoeconomic implications.
    Reckless JP
    Pharmacoeconomics; 1996 Feb; 9(2):101-5. PubMed ID: 10172696
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia.
    Lim MC; Foo WM
    Ann Acad Med Singap; 1992 Jan; 21(1):34-7. PubMed ID: 1590653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
    Pickin DM; McCabe CJ; Ramsay LE; Payne N; Haq IU; Yeo WW; Jackson PR
    Heart; 1999 Sep; 82(3):325-32. PubMed ID: 10455083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of 4S evidence on baseline lipid levels.
    Ravnskov U
    Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7603244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.